Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732653 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2022.1095592 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Revisiting malignant gastric outlet obstruction: Where do we stand?
World J Gastrointest Endosc
January 2025
Department of Pediatric Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India.
The scope of management of malignant gastric outlet obstruction is ever-expanding. The therapeutic use of endoscopy is gaining popularity not just owing to its technical advancement and satisfactory patient outcomes. With technical success rates close to 96%, stent placement for palliating gastric obstruction has ensured a median survival of about 2 months post-deployment of gastro-duodenal stents.
View Article and Find Full Text PDFInjecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.
Front Immunol
January 2025
BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia.
Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity are known and used, they often fail to achieve satisfactory long-term patient outcomes and survival. Recently, immunotherapy has shown success in patients by harnessing important interactions between the immune system and cancer.
View Article and Find Full Text PDFESAT-6 protein suppresses allograft rejection by inducing CD4Foxp3 regulatory T cells through IκBα/cRel pathway.
Front Immunol
January 2025
Section of Immunology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Background: Maintenance immunosuppression is required for suppression of alloimmunity or allograft rejection. However, continuous use of immunosuppressants may lead to various side effects, necessitating the use of alternative immunosuppressive drugs. The early secreted antigenic target of 6 kDa (ESAT-6) is a virulence factor and immunoregulatory protein of mycobacterium tuberculosis (Mtb), which alters host immunity through dually regulating development or activation of various immune cells.
View Article and Find Full Text PDFBlood flow restricted walking: does the hypoxic environment compromise walking technique?
Front Sports Act Living
January 2025
School of Human Sciences, University of Western Australia, Perth, WA, Australia.
HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms.
Front Cell Dev Biol
January 2025
Department of Cell and Cancer Biology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, United States.
Heat Shock Factor 1 (HSF1) is a major transcriptional factor regulating the heat shock response and has become a potential target for overcoming cancer chemoresistance. This review comprehensively examines HSF1's role in chemoresistance and its potential as a therapeutic target in cancer. We explore the complex, intricate mechanism that regulates the activation of HSF1, HSF1's function in promoting resistance to chemotherapy, and the strategies used to manipulate HSF1 for therapeutic benefit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!